Bevacizumab

Por Kazazi-Hyseni, Filis, Beijnen, Jos H., Schellens, Jan H. M.
Publicado em 2010

Trastuzumab

Por Boekhout, Annelies H., Beijnen, Jos H., Schellens, Jan H.M.
Publicado em 2011

Protein versus DNA as a marker for peripheral blood mononuclear cell counting

Por Jansen, Robert S., Rosing, Hilde, Schellens, Jan H. M., Beijnen, Jos H.
Publicado em 2009

Concise Drug Review: Azacitidine and Decitabine

Por Derissen, Ellen J.B., Beijnen, Jos H., Schellens, Jan H.M.
Publicado em 2013

Inhibitors of mTOR

Por Klümpen, Heinz-Josef, Beijnen, Jos H., Gurney, Howard, Schellens, Jan H.M.
Publicado em 2010

Part 3: Pharmacogenetic Variability in Phase II Anticancer Drug Metabolism

Por Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Publicado em 2011

Part 4: Pharmacogenetic Variability in Anticancer Pharmacodynamic Drug Effects

Por Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Publicado em 2011

Part 1: Background, Methodology, and Clinical Adoption of Pharmacogenetics

Por Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Publicado em 2011

Part 2: Pharmacogenetic Variability in Drug Transport and Phase I Anticancer Drug Metabolism

Por Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Publicado em 2011

Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients

Por Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
Publicado em 2013

Lapatinib for Advanced or Metastatic Breast Cancer

Por Opdam, Frans L., Guchelaar, Henk-Jan, Beijnen, Jos H., Schellens, Jan H.M.
Publicado em 2012

Concise Drug Review: Pazopanib and Axitinib

Por van Geel, Robin M.J.M., Beijnen, Jos H., Schellens, Jan H.M.
Publicado em 2012

Specific Investigation of Sample Handling Effects on Protease Activities and Absolute Serum Concentrations of Various Putative Peptidome Cancer Biomarkers

Por van den Broek, Irene, Sparidans, Rolf W., Schellens, Jan H. M., Beijnen, Jos H.
Publicado em 2010

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs

Por Kip, Anke E., Schellens, Jan H. M., Beijnen, Jos H., Dorlo, Thomas P. C.
Publicado no Clin Pharmacokinet (2017)

Treatment Individualization in Colorectal Cancer

Por van Geel, Robin M. J. M., Beijnen, Jos H., Bernards, René, Schellens, Jan H.M.
Publicado no Curr Colorectal Cancer Rep (2015)

BRAF Mutations as Predictive Biomarker for Response to Anti‐EGFR Monoclonal Antibodies

Por van Brummelen, Emilie M. J., de Boer, Anthonius, Beijnen, Jos H., Schellens, Jan H. M.
Publicado no Oncologist (2017)

Letter to the Editor Regarding “A Prospective, Controlled Study of the Botanical Compound Mixture LCS101 for Chemotherapy-Induced Hematological Complications in Breast Cancer” by Y...

Por Mooiman, Kim D., Goey, Andrew K.L., Meijerman, Irma, Beijnen, Jos H., Schellens, Jan H.M.
Publicado em 2012

Performance of Methods for Handling Missing Categorical Covariate Data in Population Pharmacokinetic Analyses

Por Keizer, Ron J., Zandvliet, Anthe S., Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R.
Publicado em 2012

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)

Por Keizer, Ron J., Zandvliet, Anthe S., Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R.
Publicado em 2011

Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges

Por van Brummelen, Emilie M.J., Ros, Willeke, Wolbink, Gertjan, Beijnen, Jos H., Schellens, Jan H.M.
Publicado no Oncologist (2016)